Showing results (121-130 of 194) with videos related to
Sort By:
Pageof 20
Cell Cycle (Georgetown, Tex.)|December 1, 2017
Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and preventionKei Kawaguchi, Qinghong Han, Shukuan Li, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2022
Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose ChemotherapyZev A Wainberg, Arun S Singh, Gottfried E Konecny, et al.Lancet (London, England)|February 15, 2016
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trialPatrick Schöffski, Sant Chawla, Robert G Maki, et al.Cancer|April 30, 2019
A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomasRobin L Jones, Sant P Chawla, Steven Attia, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2020
A Phase II Trial of 5-Day Neoadjuvant Radiotherapy for Patients with High-Risk Primary Soft Tissue SarcomaAnusha Kalbasi, Mitchell Kamrava, Fang-I Chu, et al.Cell|March 22, 2016
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic MelanomaWilly Hugo, Jesse M Zaretsky, Lu Sun, et al.Rapid Communications in Mass Spectrometry : RCM|March 5, 2014
Rapid detection and quantification of apolipoprotein L1 genetic variants and total levels in plasma by ultra-performance liquid chromatography/tandem mass spectrometryHaihong Zhou, Maarten Hoek, Pan Yi, et al.Cancer|August 18, 2016
Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodiesAlain P Algazi, Katy K Tsai, Alexander N Shoushtari, et al.Cancer|January 23, 2024
A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancersAlain P Algazi, James Moon, Christopher D Lao, et al.Journal of Translational Medicine|September 30, 2010
Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanomaAntoni Ribas, Luis H Camacho, Sun Min Lee, et al.Pageof 20